Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
by Liz Hanson | Nov 10, 2021 | Uncategorized | 0 comments
by Liz Hanson | Nov 10, 2021 | Uncategorized | 0 comments